首页> Cancer discovery> Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers.

Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers.

导出 LinkOut

翻译打印收藏纠错

第一作者： Vivek,Subbiah

第一单位： Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

作者： Vivek,Subbiah ^[1] ; Justin F,Gainor ^[2] ; Rami,Rahal ^[3] ; Jason D,Brubaker ^[3] ; Joseph L,Kim ^[3] ; Michelle,Maynard ^[3] ; Wei,Hu ^[3] ; Qiongfang,Cao ^[3] ; Michael P,Sheets ^[3] ; Douglas,Wilson ^[3] ; Kevin J,Wilson ^[3] ; Lucian,DiPietro ^[3] ; Paul,Fleming ^[3] ; Michael,Palmer ^[3] ; Mimi I,Hu ^[4] ; Lori,Wirth ^[2] ; Marcia S,Brose ^[5] ; Sai-Hong Ignatius,Ou ^[6] ; Matthew,Taylor ^[7] ; Elena,Garralda ^[8] ; Stephen,Miller ^[3] ; Beni,Wolf ^[3] ; Christoph,Lengauer ^[3] ; Timothy,Guzi ^[3] ; Erica K,Evans ^[9]

作者单位： Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. ^[1] Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. ^[2] Blueprint Medicines Corporation, Cambridge, Massachusetts. ^[3] Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas. ^[4] Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania. ^[5] Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Irvine, California. ^[6] The Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon. ^[7] Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. ^[8] Blueprint Medicines Corporation, Cambridge, Massachusetts. eevans@blueprintmedicines.com. ^[9]